Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 8, 2026, by Tango Therapeutics, Inc. The filing discloses initial safety and efficacy data from a Phase 1/2 combination trial evaluating the Company's investigational drug, vopimetostat, in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. The data cutoff date for the reported clinical results was May 28, 2026.
Key Clinical Metrics and Financial Status
Clinical Trial Results (Vopimetostat + Daraxonrasib):
- Population: 12 response-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 3 with non-small cell lung cancer (NSCLC).
- PDAC Efficacy: 92% Objective Response Rate (ORR) (11 of 12 patients); 90% six-month progression-free survival rate; 100% Disease Control Rate (DCR).
- NSCLC Efficacy: 100% ORR (3 of 3 patients).
- Safety: Generally well tolerated; most adverse events were Grade 1 or 2. No Grade 4 or 5 adverse events related to the combination. No discontinuations due to adverse events.
Clinical Trial Results (Vopimetostat + Zoldonrasib):
- Population: 27 response-evaluable patients with PDAC.
- Efficacy: 52% ORR; 74% six-month progression-free survival rate; 96% DCR.
- Safety: Generally well tolerated; no Grade 4 or 5 adverse events or dose-limiting toxicities (DLTs).
Financial Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial disclosures.
Material Changes and Strategic Outlook
Based on the positive data from the vopimetostat plus daraxonrasib arm, the Company intends to advance this combination into Phase 3 development for patients with MTAP-deleted pancreatic cancer. Management plans to initiate a Phase 3 randomized-controlled trial in front-line pancreatic cancer, subject to regulatory feedback. The Company also intends to evaluate opportunities to advance the second-line combination towards the registration phase.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Clinical trial results may not be replicated in later studies or broader populations.
- Regulatory developments in the U.S. and foreign countries.
- The Company's ability to fund operations.
- Timing of future clinical trial data releases may differ from expectations.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and data presentation (Exhibit 99.2) for detailed statistical analysis.
- Confirm the specific regulatory feedback required before initiating the planned Phase 3 trial.
- Review the Company's most recent Form 10-K or 10-Q to assess current cash runway and funding status, as this 8-K does not contain financial data.
- Monitor for updates on the safety profile of the vopimetostat plus daraxonrasib combination as the patient cohort expands.